FDA AI Tool: 4 Key Updates | Becker’s Hospital Review
- The Food and Drug Administration (FDA) has implemented a generative artificial intelligence tool, Elsa, across it's agency to enhance staff efficiency and improve internal workflows.
- Currently, Elsa is being used to accelerate the review of clinical trial protocols, shorten the time required to analyze scientific data, and pinpoint the agency’s most pressing inspection...
- Jeremy Walsh, the FDA’s chief AI officer, stated in a June 2 news release that the development team will continue to add capabilities based on employee usage and...
Teh FDA has launched Elsa,an agencywide AI tool,set to revolutionize internal processes and boost efficiency.This generative AI integration will streamline clinical trial reviews, accelerate data analysis, and improve product safety assessments. The secure GovCloud platform powers Elsa, developed to meet the FDA’s specific needs and employee usage, with the latest updates as of June 3, 2025. Key features include summarizing adverse events and generating code for FDA databases. The successful pilot program and June 30 deadline for agency-wide integration, as reported by News Directory 3, signal a significant leap forward. The generative AI aims to optimize performance for the American people. Discover what’s next and the ongoing evolution of this powerful tool.
FDA Launches AI Tool Elsa to Boost Efficiency
The Food and Drug Administration (FDA) has implemented a generative artificial intelligence tool, Elsa, across it’s agency to enhance staff efficiency and improve internal workflows. The AI tool aims to streamline various processes, from clinical trial reviews to data analysis.
Currently, Elsa is being used to accelerate the review of clinical trial protocols, shorten the time required to analyze scientific data, and pinpoint the agency’s most pressing inspection priorities. The AI integration also helps in summarizing adverse events for product safety assessment, conducting rapid label comparisons, and generating code for internal FDA databases.
Jeremy Walsh, the FDA’s chief AI officer, stated in a June 2 news release that the development team will continue to add capabilities based on employee usage and agency needs. The generative AI operates within GovCloud, a secure platform used by federal agencies for managing sensitive data. It is powered by a large language model but does not train on data submitted by regulated entities.
“As we learn how employees are using the tool, our development team will be able to add capabilities and grow with the needs of employees and the agency,”
Jeremy Walsh, FDA Chief AI Officer
What’s next
This agencywide rollout follows a successful pilot program and aligns with the june 30 deadline set by FDA Commissioner Martin makary, MD, to fully integrate the tool across all FDA centers.